Streetbeat News

THRD

Third Harmonic Bio, Inc.

https://www.thirdharmonicbio.com

Industry

Biotechnology

Third Harmonic Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of the medicine for the treatment of allergic and inflammatory diseases. It develops THB001, an oral small-molecule KIT inhibitor for the treatment of chronic urticaria, a dermatologic disease driven by mast cell activation that results in red, itchy, painful welts, or hives, as well as for airway and gastrointestinal tract indications. The company was formerly known as Project IGE, Inc. and changed its name to Third Harmonic Bio, Inc. in June 2019. Third Harmonic Bio, Inc. was founded in 2019 and is headquartered in Cambridge, Massachusetts.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Third Harmonic shares are trading higher following strong Q2 financial results and an upgrade from Morgan Stanley, which raised its price target from $12 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 3:45 pm

Morgan Stanley has upgraded Third Harmonic Bio (NASDAQ:THRD) from Equal-Weight to Overweight and raised the price target from $12 to $20.

Portfolio Pulse from Benzinga Newsdesk

August 09, 2024 | 9:28 am

Third Harmonic Bio (NASDAQ:THRD) reported a Q2 2024 adjusted EPS of $(0.19), beating the analyst consensus estimate of $(0.27) by 29.63%.

Portfolio Pulse from Benzinga Newsdesk

August 08, 2024 | 12:17 pm

Stifel analyst Alex Thompson has initiated coverage on Third Harmonic Bio (NASDAQ:THRD) with a Buy rating and set a price target of $23.

Portfolio Pulse from Benzinga Newsdesk

June 18, 2024 | 9:14 am

Raymond James has initiated coverage on Third Harmonic Bio (NASDAQ:THRD) with an Outperform rating and set a price target of $18.

Portfolio Pulse from Benzinga Newsdesk

June 07, 2024 | 9:23 am

Third Harmonic Bio (NASDAQ:THRD) reported a Q1 2024 adjusted EPS of $(0.20), beating the analyst consensus estimate of $(0.31) by 35.48%.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:10 pm

Third Harmonic Bio (NASDAQ:THRD) reported Q4 earnings with losses of $(0.17) per share, surpassing the analyst consensus estimate of $(0.31) by 45.16%. This represents a 52.78% improvement over the previous year's losses of $(0.36) per share.

Portfolio Pulse from Happy Mohamed

March 26, 2024 | 1:26 pm

Third Harmonic Bio (NASDAQ:THRD) reported Q4 earnings, beating estimates with an EPS of $-0.17 versus the expected $-0.31. However, revenue remained unchanged from the previous year. The company had previously beaten EPS estimates last quarter, which led to a 1.0% increase in share price the following day.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:25 pm

Third Harmonic Bio reported a FY23 EPS of $(0.78), an improvement from $(2.45) YoY. The company's cash position is strong at $269.1 million, expected to support operations through 2026. R&D expenses decreased slightly, while G&A expenses rose due to the costs of being a public company. The net loss for the year narrowed to $30.8 million from $35.2 million.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:20 pm

Third Harmonic Bio reported a Q4 net loss of $6.8 million, but maintains a strong cash balance of $269.1 million, indicating financial stability despite the loss.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:14 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.